Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Neurology

The SPSD Spectrum: Understanding Your Variant

At a Glance

Stiff Person Spectrum Disorder (SPSD) includes several variants, such as Classic SPS, Stiff-Limb Syndrome, and PERM. Identifying your specific subtype and underlying antibodies is crucial, as it determines which muscles are affected, your symptom severity, and the most effective treatment plan.

Because Stiff Person Spectrum Disorder (SPSD) is a “spectrum,” no two patients experience the disease in exactly the same way. Doctors use specific subtypes to categorize the condition based on which muscles are affected, how quickly it progresses, and which antibodies are found in the blood [1].

Classic Stiff Person Syndrome

This is the most common form of the disorder. It is characterized by progressive muscle rigidity and painful spasms that primarily affect the axial muscles (the trunk, including the back and abdomen) [2].

  • Physical Signs: Patients often develop a fixed, arched posture in the lower back and may have difficulty bending or twisting.
  • Antibody Connection: Most classic cases are associated with high levels of anti-GAD65 antibodies [3].

Stiff-Limb Syndrome (SLS)

In this variant, the stiffness and spasms are initially restricted to one or more limbs, most often the legs [4].

  • Physical Signs: Patients may have a “stiff-legged” gait or find that one foot becomes fixed in an unusual position.
  • Progression: While it starts in the limbs, SLS can sometimes progress to involve the trunk over time. Like the classic form, it is often linked to anti-GAD65 antibodies [5].

PERM: A Severe Variant

Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM) is a more aggressive and widespread version of SPSD [6].

  • Key Differences: Beyond stiffness, PERM involves the brainstem and autonomic nervous system. This can cause myoclonus (sudden muscle jerks), issues with eye movements, and “dysautonomia” (problems with heart rate, blood pressure, or temperature control) [7].
  • The GlyR Antibody: While GAD65 can be involved, PERM is strongly associated with anti-GlyR (glycine receptor) antibodies, which directly block “stop” signals in the spinal cord and brainstem [7].

SPSD-Plus and Overlap Syndromes

Some patients have the typical stiffness of SPSD but also show signs of other neurological issues. This is sometimes referred to as SPS-Plus [8].

  • Associated Features: This may include cerebellar ataxia (problems with balance and coordination), epilepsy (seizures), or limbic encephalitis (memory or mood changes) [9].
  • Significance: These extra features often suggest the immune system is targeting multiple areas of the central nervous system, not just the motor pathways [10].

Why Subtypes Matter

Identifying your subtype is not just about giving the disease a name; it helps your medical team determine your prognosis (expected outcome) and the best treatment plan [11].

  • Treatment Response: Patients with PERM or specific antibody types may require more aggressive immunotherapy, such as plasma exchange or rituximab, compared to those with classic SPS [12].
  • Underlying Causes: Certain subtypes, particularly those involving anti-amphiphysin antibodies, are more likely to be “paraneoplastic,” meaning they are triggered by a hidden cancer (like breast cancer) that must be treated for the SPSD to improve [13][14].

Common questions in this guide

What is Classic Stiff Person Syndrome?
Classic Stiff Person Syndrome is the most common form of the disorder. It causes progressive muscle rigidity and painful spasms that primarily affect the trunk, back, and abdomen, often leading to a fixed, arched posture.
How is Stiff-Limb Syndrome different from classic SPS?
In Stiff-Limb Syndrome, muscle stiffness and spasms are initially restricted to one or more limbs, usually the legs. While it begins in the limbs, it can sometimes progress over time to involve the trunk as well.
What does it mean to have the PERM variant of SPSD?
PERM is a more severe and aggressive variant that affects the brainstem and autonomic nervous system. In addition to muscle stiffness, it can cause sudden muscle jerks, eye movement issues, and problems with heart rate and blood pressure control.
What is SPS-Plus?
SPS-Plus refers to cases where a patient has typical muscle stiffness but also experiences extra neurological issues. These additional symptoms can include problems with balance and coordination, seizures, or changes in memory and mood.
Why does my SPSD subtype matter for treatment?
Your specific subtype and antibody profile help doctors predict your prognosis and choose the best therapy. For example, severe variants like PERM may require more aggressive immunotherapy treatments like plasma exchange or rituximab compared to classic SPS.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my symptoms and antibody test results, which specific SPSD subtype do I have?
  2. 2.Does the presence of anti-GlyR antibodies in my case mean I am at higher risk for brainstem or autonomic symptoms?
  3. 3.Given that I have symptoms beyond muscle stiffness, such as balance issues or seizures, do I meet the criteria for SPS-Plus?
  4. 4.Does my specific subtype change how aggressively we should pursue immunotherapy versus symptomatic treatments?
  5. 5.If my symptoms are focal like Stiff-Limb Syndrome, is it likely they will eventually spread to my trunk or other limbs?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Pragmatic Treatment of Stiff Person Spectrum Disorders.

    Balint B, Meinck HM

    Movement disorders clinical practice 2018; (5(4)):394-401 doi:10.1002/mdc3.12629.

    PMID: 30363317
  2. 2

    Intranasal midazolam for treating acute respiratory crises in a woman with stiff person syndrome.

    Cosentino G, Romano M, Algeri M, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2020; (7(4)) doi:10.1212/NXI.0000000000000715.

    PMID: 32238523
  3. 3

    Quantitative Assessment of Response to Long-Term Treatment with Intravenous Immunoglobulin in Patients with Stiff Person Syndrome.

    Bose S, Thompson JP, Sadalage G, et al.

    Movement disorders clinical practice 2021; (8(6)):868-874 doi:10.1002/mdc3.13261.

    PMID: 34401404
  4. 4

    Stiff-person syndrome: an atypical presentation and a review of the literature.

    Lin BC, Johal J, Sivakumar K, et al.

    Hospital practice (1995) 2021; (49(5)):384-390 doi:10.1080/21548331.2021.1961456.

    PMID: 34313523
  5. 5

    [Stiff-Person Syndrome].

    Matsui N, Tanaka K, Izumi Y

    Brain and nerve = Shinkei kenkyu no shinpo 2023; (75(6)):749-754 doi:10.11477/mf.1416202410.

    PMID: 37287358
  6. 6

    Progressive Encephalomyelitis With Rigidity and Myoclonus Syndrome Presenting as Catatonia.

    Witek N, Hebert C, Gera A, Comella C

    Psychosomatics 2019; (60(1)):83-87 doi:10.1016/j.psym.2018.05.005.

    PMID: 30143326
  7. 7

    Successful Treatment of Glycine-Receptor-Antibody-Mediated Progressive Encephalomyelitis with Rigidity and Myoclonus by Combining Steroids and Azathioprine.

    Lee EJ, Kim K, Choi JY, Park KS

    Journal of clinical neurology (Seoul, Korea) 2019; (15(4)):581-582 doi:10.3988/jcn.2019.15.4.581.

    PMID: 31591852
  8. 8

    Clinical and Immunologic Investigations in Patients With Stiff-Person Spectrum Disorder.

    Martinez-Hernandez E, Ariño H, McKeon A, et al.

    JAMA neurology 2016; (73(6)):714-20 doi:10.1001/jamaneurol.2016.0133.

    PMID: 27065452
  9. 9

    GAD65 autoimmunity after treatment with nivolumab: a multifocal presentation.

    Maniscalco GT, Zekeridou A, Allegorico L, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(10)):4289-4291 doi:10.1007/s10072-021-05312-0.

    PMID: 33977307
  10. 10

    GAD antibodies in neurological disorders - insights and challenges.

    Graus F, Saiz A, Dalmau J

    Nature reviews. Neurology 2020; (16(7)):353-365 doi:10.1038/s41582-020-0359-x.

    PMID: 32457440
  11. 11

    A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome.

    Dalakas MC, Rakocevic G, Dambrosia JM, et al.

    Annals of neurology 2017; (82(2)):271-277 doi:10.1002/ana.25002.

    PMID: 28749549
  12. 12

    Successful Autologous Hematopoietic Stem Cell Transplant in Glycine Receptor Antibody-Positive Stiff Person Syndrome: A Case Report

    Celli SI, Nash R, Money KM, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2024; (11(2)):e200197 doi:10.1212/NXI.0000000000200197.

    PMID: 38170953
  13. 13

    Stiff-Person Syndrome with Anti-Amphiphysin Antibodies: A Paraneoplastic Phenomenon Revealing Breast Cancer in a 77-Year-Old Male.

    Geyskens M, Roos DS, Konings IR, et al.

    Case reports in neurology 2026; (18(1)):1-8 doi:10.1159/000549746.

    PMID: 41445546
  14. 14

    Anti-glutamic acid decarboxylase 65: Related stiff person syndrome - A report of two cases and literature review.

    Naoe EEL, Durano RR, De Roxas-Bernardino RC, Saranza G

    SAGE open medical case reports 2025; (13()):2050313X251333676 doi:10.1177/2050313X251333676.

    PMID: 40308378

This page provides educational information about Stiff Person Spectrum Disorder (SPSD) variants. Always consult your neurologist for an accurate diagnosis and treatment plan tailored to your specific subtype.

Get notified when new evidence is published on Stiff person spectrum disorder.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.